PPARG and kidney disorder: Interestingly, as a member of the RAAS inhibitors is widely used in the treatment of renal disease, telmisartan (characterized as selective PPARγ modulators in 2005) had advantages in reducing albuminuria, serum creatinine, and glomerulosclerosis in a nondiabetic model by its partial agonistic activity on PPARγ.